Targets › CDH6
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. (UniProt, P55285)
Open in Phaseline: the race on CDH6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hansoh BioMedical R&D Company | HS-20124 anti-CDH6 antibody-drug conjugate (DAR-8) | CDH6 | Phase 1 | Solid Cancer | Dec 2026 |
| Phrontline Biopharma | TJ102 CDH6/FRα directed antibody-drug conjugate with dual payloads | CDH6, FOLR1 | Phase 1 | Ovarian Cancer | Sep 2029 |
Ovarian Cancer (1) Solid Cancer (1)
protein or peptide (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.